Trials / Terminated
TerminatedNCT04418648
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
A Phase II, Randomised Study of Toripalimab as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The phase II, randomised study is to explore the efficacy and safety of toripalimab as consolidation therapy in patients with limited-stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | Toripalimab consolidation (240 mg) via iv infusion once every 3 weeks. Administration of toripalimab will commence on Day 1 following randomisation to toripalimab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 6 months. |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2020-06-05
- Last updated
- 2026-02-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04418648. Inclusion in this directory is not an endorsement.